showed that treatment of mice bearing colon cancer with a combination of anti-PD-1/PD-L1 and a chimeric anti-SIRPα neutralizing antibody was highly effective in suppressing growth of primary tumors.54 This evidence concerns the gene SIRPA and malignant colon neoplasm.